Log in

SeaSpine Stock Forecast, Price & News

+0.02 (+0.14 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $14.04
50-Day Range
MA: $12.83
52-Week Range
Now: $14.04
Volume290,839 shs
Average Volume211,832 shs
Market Capitalization$386.41 million
P/E RatioN/A
Dividend YieldN/A
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. The company was incorporated in 2015 and is headquartered in Carlsbad, California.
Read More
SeaSpine logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:SPNE



Sales & Book Value

Annual Sales$159.08 million
Book Value$5.74 per share


Net Income$-39,280,000.00


Market Cap$386.41 million
Next Earnings Date11/3/2020 (Estimated)
+0.02 (+0.14 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SPNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SPNE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

SeaSpine (NASDAQ:SPNE) Frequently Asked Questions

How has SeaSpine's stock price been impacted by Coronavirus?

SeaSpine's stock was trading at $10.73 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SPNE stock has increased by 30.8% and is now trading at $14.04.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of SeaSpine?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for SeaSpine

When is SeaSpine's next earnings date?

SeaSpine is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for SeaSpine

How were SeaSpine's earnings last quarter?

SeaSpine Holdings Corp (NASDAQ:SPNE) posted its quarterly earnings results on Tuesday, August, 4th. The medical equipment provider reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.20. The medical equipment provider had revenue of $28.59 million for the quarter, compared to the consensus estimate of $20.90 million. SeaSpine had a negative return on equity of 29.03% and a negative net margin of 30.01%.
View SeaSpine's earnings history

What price target have analysts set for SPNE?

5 Wall Street analysts have issued 12 month price objectives for SeaSpine's stock. Their forecasts range from $10.00 to $21.00. On average, they expect SeaSpine's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 14.0% from the stock's current price.
View analysts' price targets for SeaSpine

Are investors shorting SeaSpine?

SeaSpine saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 490,300 shares, a decline of 16.0% from the August 15th total of 583,800 shares. Based on an average trading volume of 192,700 shares, the short-interest ratio is currently 2.5 days.
View SeaSpine's Short Interest

Who are some of SeaSpine's key competitors?

What other stocks do shareholders of SeaSpine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SeaSpine investors own include Corbus Pharmaceuticals (CRBP), Kura Oncology (KURA), Madrigal Pharmaceuticals (MDGL), Recro Pharma (REPH), Rigel Pharmaceuticals (RIGL), Spectrum Pharmaceuticals (SPPI), Viewray (VRAY), Verastem (VSTM), Amarin (AMRN) and Athenex (ATNX).

Who are SeaSpine's key executives?

SeaSpine's management team includes the following people:
  • Mr. Keith C. Valentine, Pres, CEO & Director (Age 51)
  • Mr. John J. Bostjancic, Sr. VP, CFO & Treasurer (Age 48)
  • Mr. Patrick L. Keran, VP, Gen. Counsel & Corp. Sec. (Age 47)
  • Carrie Mendivil, Head of Investor Relations
  • Mr. John J. Winge, VP of Sales (Age 52)

What is SeaSpine's stock symbol?

SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."

Who are SeaSpine's major shareholders?

SeaSpine's stock is owned by many different retail and institutional investors. Top institutional shareholders include First Light Asset Management LLC (18.58%), Driehaus Capital Management LLC (4.87%), Silvercrest Asset Management Group LLC (1.55%), Emerald Advisers LLC (1.26%), Emerald Mutual Fund Advisers Trust (1.15%) and Mutual of America Capital Management LLC (0.69%). Company insiders that own SeaSpine stock include John B Henneman III, Keith Valentine, Richard E Caruso and Stuart Essig.
View institutional ownership trends for SeaSpine

Which institutional investors are selling SeaSpine stock?

SPNE stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Silvercrest Asset Management Group LLC, Falcon Point Capital LLC, Wedge Capital Management L L P NC, Driehaus Capital Management LLC, Two Sigma Advisers LP, Engineers Gate Manager LP, and Alyeska Investment Group L.P.. Company insiders that have sold SeaSpine company stock in the last year include John B Henneman III, and Richard E Caruso.
View insider buying and selling activity for SeaSpine

Which institutional investors are buying SeaSpine stock?

SPNE stock was acquired by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Goldman Sachs Group Inc., Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Nuveen Asset Management LLC, AQR Capital Management LLC, California Public Employees Retirement System, and Bessemer Group Inc..
View insider buying and selling activity for SeaSpine

How do I buy shares of SeaSpine?

Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SeaSpine's stock price today?

One share of SPNE stock can currently be purchased for approximately $14.04.

How big of a company is SeaSpine?

SeaSpine has a market capitalization of $386.41 million and generates $159.08 million in revenue each year. The medical equipment provider earns $-39,280,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis. SeaSpine employs 361 workers across the globe.

What is SeaSpine's official website?

The official website for SeaSpine is www.seaspine.com.

How can I contact SeaSpine?

SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-727-8399 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.